Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

被引：7
|
作者：
Diefenbach, Catherine S. [1 ]
Jegede, Opeyemi [2 ]
Ansell, Stephen M. [3 ]
Steidl, Christian [4 ]
Natkunam, Yasodha [5 ,6 ]
Scott, David W. [7 ]
Mehta-Shah, Neha [8 ]
Amengual, Jennifer E. [9 ]
Forlenza, Christopher J. [10 ]
Cole, Peter D. [11 ]
Bartlett, Nancy L. [12 ]
David, Kevin A. [13 ]
Advani, Ranjana H. [14 ]
Ambinder, Richard F. [15 ]
Thomas, Sachdev [16 ]
Ibrahimi, Sami [17 ]
Kahl, Brad S. [18 ]
机构：
[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[2] CIMAC CIDC Network, Dept Data Sci, Boston, MA USA
[3] Mayo Clin, Div Hematol, Rochester, MN USA
[4] BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada
[5] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA USA
[6] Stanford Univ, Med Ctr, Stanford, CA USA
[7] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada
[8] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA
[9] Columbia Univ, Div Hematol & Oncol, Lymphoma Program, Irving Med Ctr, New York, NY USA
[10] Mem Sloan Kettering Canc Ctr, West Harrison, NY USA
[11] NJ Rbt Wood Johnson Univ Hosp, Rutgers Ca Inst, New Brunswick, NJ USA
[12] Washington Univ, Siteman, Sch Med, St Louis, MO USA
[13] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[14] Stanford Univ, Div Hematol & Oncol, Dept Med, Stanford, CA USA
[15] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[16] VA Cent Calif Hlth CARE Syst, Fresno, CA USA
[17] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[18] Washington Univ, Sch Med St Louis, St Louis, MO USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184531
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Preliminary Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 15 - 18
  • [32] Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Song, Yuqin
    Guo, Ye
    Huang, Huiqiang
    Li, Wei
    Ke, Xiaoyan
    Feng, Jifeng
    Xu, Wei
    Miao, Harry
    Kinley, Judith
    Song, Gregory
    Dai, Yi
    Wang, Hui
    Zhu, Jun
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 867 - 875
  • [33] Low-Dose Radiation Therapy with Nivolumab in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of the Phase II Radvax Trial
    LaRiviere, Michael J.
    Vaziri, Tina
    Farwell, Michael
    Maity, Amit
    Paydar, Ima
    Schuster, Stephen J.
    Nasta, Sunita Dwivedy
    Chong, Elise A.
    Landsburg, Daniel J.
    Plastaras, John P.
    Svoboda, Jakub
    BLOOD, 2022, 140 : 3726 - 3727
  • [34] Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children's Oncology Group report
    Cole, Peter D.
    Metzger, Monika
    Drachtman, Richard A.
    Horton, Terzah M.
    Liu, Xiaowei
    Ahern, Charlotte H.
    Minard, Charles
    Fox, Elizabeth
    Blaney, Susan
    Weigel, Brenda
    Kelly, Kara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
    Advani, Ranjana H.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zak, Daniel E.
    Sacchi, Mariana
    Galderisi, Faith
    Herrera, Alex F.
    BLOOD, 2018, 132
  • [36] Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)
    M. Margaret Kemeny
    Fengmin Zhao
    Arlene A. Forastiere
    Paul Catalano
    Stanley R. Hamilton
    Brent W. Miedema
    Nancy A. Dawson
    Louis M. Weiner
    Brian D. Smith
    Bernard A. Mason
    Stephen L. Graziano
    Paul B. Gilman
    Alan P. Venook
    Harlan A. Pinto
    Robert P. Whitehead
    Peter J. O’Dwyer
    Al B. Benson
    Annals of Surgical Oncology, 2023, 30 : 1099 - 1109
  • [37] Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial
    Karuturi, Meghan
    Younes, Anas
    Fayad, Luis
    Kwak, Larry
    Pro, Barbara
    Shah, Jatin
    Oki, Yasuhiro
    Simien, Rinata
    Liboon, Mary Joy
    Hutto, Toni
    Feng, Lei
    Horowitz, Sandra
    Nieto, Yago
    Anderlini, Paolo
    Alousi, Amin
    Popat, Uday
    Medeiros, L. Jeffrey
    Miranda, Roberto
    Fanale, Michelle
    LEUKEMIA & LYMPHOMA, 2016, 57 (02) : 445 - 447
  • [38] Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
    Pro, Barbara
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle
    Connors, Joseph M.
    Yang, Yin
    Sievers, Eric L.
    Kennedy, Dana A.
    Shustov, Andrei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2190 - 2196
  • [39] Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)
    Kemeny, M. Margaret
    Zhao, Fengmin
    Forastiere, Arlene A.
    Catalano, Paul
    Hamilton, Stanley R.
    Miedema, Brent W.
    Dawson, Nancy A.
    Weiner, Louis M.
    Smith, Brian D.
    Mason, Bernard A.
    Graziano, Stephen L.
    Gilman, Paul B.
    Venook, Alan P.
    Pinto, Harlan A.
    Whitehead, Robert P.
    O'Dwyer, Peter J.
    Benson, Al B.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (02) : 1099 - 1109
  • [40] A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
    Kunz, Pamela L.
    Catalano, Paul J.
    Nimeiri, Halla
    Fisher, George A.
    Longacre, Teri A.
    Suarez, Carlos J.
    Yao, James C.
    Kulke, Matthew H.
    Hendifar, Andrew Eugene
    Shanks, James Christopher
    Shah, Manisha H.
    Zalupski, Mark
    Schmulbach, Edmond L.
    Reidy, Diane Lauren
    Strosberg, Jonathan R.
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345